MA47121A - Molécules de liaison pour le traitement du cancer - Google Patents
Molécules de liaison pour le traitement du cancerInfo
- Publication number
- MA47121A MA47121A MA047121A MA47121A MA47121A MA 47121 A MA47121 A MA 47121A MA 047121 A MA047121 A MA 047121A MA 47121 A MA47121 A MA 47121A MA 47121 A MA47121 A MA 47121A
- Authority
- MA
- Morocco
- Prior art keywords
- binding molecules
- cancer treatment
- cancer
- treatment
- molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437770P | 2016-12-22 | 2016-12-22 | |
| EP17155973.5A EP3360898A1 (fr) | 2017-02-14 | 2017-02-14 | Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47121A true MA47121A (fr) | 2019-10-30 |
Family
ID=58043942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047121A MA47121A (fr) | 2016-12-22 | 2017-12-21 | Molécules de liaison pour le traitement du cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10858438B2 (fr) |
| EP (2) | EP3360898A1 (fr) |
| JP (1) | JP7196076B2 (fr) |
| KR (1) | KR102651761B1 (fr) |
| CN (1) | CN110582513B (fr) |
| AU (1) | AU2017384687B2 (fr) |
| BR (1) | BR112019011750A2 (fr) |
| CA (1) | CA3046591A1 (fr) |
| CO (1) | CO2019006320A2 (fr) |
| EA (1) | EA201991480A1 (fr) |
| MA (1) | MA47121A (fr) |
| MX (1) | MX391650B (fr) |
| PE (1) | PE20191251A1 (fr) |
| TW (1) | TWI790219B (fr) |
| WO (1) | WO2018115231A2 (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3360898A1 (fr) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer |
| WO2019222428A1 (fr) * | 2018-05-16 | 2019-11-21 | Arbele Limited | Composition d'anticorps bispécifiques et procédé d'utilisation associé |
| EP3725370A1 (fr) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Anticorps anti-pd-l1 modifiés et procédés et utilisations pour le traitement d'une maladie neurodégénérative |
| CN115916779B (zh) * | 2020-05-11 | 2025-09-16 | 克立弗治疗学股份有限公司 | 用于治疗癌症的VCP/p97抑制剂 |
| JP2023504675A (ja) * | 2020-05-19 | 2023-02-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ガンの処置のための結合分子 |
| EP4277904A1 (fr) | 2021-01-15 | 2023-11-22 | Seagen Inc. | Conjugués anticorps-médicament immunomodulateurs |
| MX2023009113A (es) | 2021-02-03 | 2023-08-10 | Seagen Inc | Conjugados y compuestos inmunoestimulantes. |
| KR20240017937A (ko) * | 2021-06-07 | 2024-02-08 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | 치료제의 표적화된 전달을 위한 조성물 및 방법 |
| CN113512117B (zh) * | 2021-07-12 | 2023-08-22 | 武汉麦考津生物科技有限公司 | 一种可结合cd206的抗体及其应用 |
| US20250270314A1 (en) * | 2021-08-02 | 2025-08-28 | Tavotek Biotech (Suzhou) Ltd | Anti-cdh17 monoclonal and bispecific antibodies and uses thereof |
| WO2023023677A1 (fr) * | 2021-08-20 | 2023-02-23 | University Of Virginia Patent Foundation | Stratégie pour l'activation de dr5 hautement supérieure, notamment dans des tumeurs et des cancers |
| EP4518905A1 (fr) | 2022-05-06 | 2025-03-12 | Seagen Inc. | Conjugués anticorps-médicament immunomodulateurs |
| WO2024013315A1 (fr) | 2022-07-15 | 2024-01-18 | Boehringer Ingelheim International Gmbh | Molécules de liaison pour le traitement du cancer |
| IL318450A (en) | 2022-08-03 | 2025-03-01 | Seagen Inc | Immunostimulatory ANTI-PD-L1-Drug conjugates |
| EP4321522A1 (fr) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Composés cytotoxiques et conjugués de ceux-ci |
| JP2025534663A (ja) * | 2022-10-14 | 2025-10-17 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | 治療薬の標的化送達のための組成物及び方法 |
| CN115785269B (zh) * | 2022-11-01 | 2023-09-22 | 四川大学 | 抗pd-l1的抗体及其应用 |
| KR20250134582A (ko) | 2022-11-10 | 2025-09-11 | 이뮤비아 인코포레이티드 | Dr5 및 muc16에 결합하는 세포독성 이중특이성 항체 및 이의 용도 |
| EP4669672A1 (fr) | 2023-02-23 | 2025-12-31 | Hansoh Bio LLC | Anticorps, fragments de liaison à l'antigène et procédés d'utilisation |
| WO2025072182A2 (fr) * | 2023-09-25 | 2025-04-03 | Trio Pharmaceuticals, Inc. | Activation ciblée de mort cellulaire endogène |
| KR20260116002A (ko) * | 2023-11-23 | 2026-07-27 | 라노바 메디신즈 리미티드 | 항-cdh17 항체 및 이의 접합체 |
| CN120230211A (zh) | 2023-12-29 | 2025-07-01 | 广东菲鹏制药股份有限公司 | 抗cdh17抗体或其抗原结合片段及其应用 |
| WO2025242099A1 (fr) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | Conjugué anticorps-médicament contre cdh17 et son utilisation |
| WO2025261505A1 (fr) * | 2024-06-21 | 2025-12-26 | 映恩生物制药（苏州）有限公司 | Conjugué médicament-anticorps anti-cdh17 et son utilisation |
| US20260078179A1 (en) | 2024-07-18 | 2026-03-19 | Novarock Biotherapeutics, Ltd. | Cdh17 antibodies and uses thereof |
| WO2026017120A1 (fr) * | 2024-07-18 | 2026-01-22 | 信达生物制药(苏州)有限公司 | Anticorps trispécifique anti-cdh17/egfr/cd16a et son utilisation |
| WO2026046327A1 (fr) * | 2024-08-29 | 2026-03-05 | Utc Therapeutics (Shanghai) Co., Ltd. | Anticorps ciblant cdh17, récepteurs antigéniques chimériques et leurs utilisations |
| CN119310289A (zh) * | 2024-10-31 | 2025-01-14 | 新疆维吾尔自治区人民医院 | On的检测试剂在辅助诊断急性胸痛疾病中的应用 |
| WO2026136620A1 (fr) * | 2024-12-19 | 2026-06-25 | Odyssey Therapeutics, Inc. | Molécules multispécifiques se liant à trailr2 et cdh17 et leurs utilisations |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US168A (en) | 1837-04-17 | Improvement in fire-arms | ||
| US5731A (en) | 1848-08-22 | Elisha k | ||
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0281604B1 (fr) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Molecules de liaison de chaines de polypeptide simples |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| CA2163032C (fr) | 1993-06-03 | 2001-02-06 | John Landon | Fragments d'anticorps a des fins therapeutiques |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6323322B1 (en) | 1997-04-30 | 2001-11-27 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1361892A4 (fr) | 2001-01-17 | 2004-10-13 | Trubion Pharmaceuticals Inc | Proteines de fusion d'immunoglobuline de domaine de liaison |
| EP1456410A2 (fr) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Procede d'affichage de boucles de domaines d'immunoglobuline dans differents contextes |
| JP2005516958A (ja) * | 2001-12-20 | 2005-06-09 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | Ｔｒａｉｌレセプターに免疫特異的に結合する抗体 |
| CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| JP5087274B2 (ja) | 2003-06-30 | 2012-12-05 | ドマンティス リミテッド | ポリペプチド |
| CA2534898A1 (fr) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Anticorps bispecifiques pour induire l'apoptose de cellules tumorales et malades |
| US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| US20060228352A1 (en) | 2005-02-24 | 2006-10-12 | Schoenberger Stephen P | TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL |
| CN101287764B (zh) | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| EP3663318A1 (fr) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique |
| NZ616382A (en) * | 2009-04-20 | 2015-04-24 | Oxford Biotherapeutics Ltd | Antibodies specific to cadherin-17 |
| PL2483310T3 (pl) * | 2009-09-29 | 2015-01-30 | Roche Glycart Ag | Bispecyficzne przeciwciała agonistyczne dla receptora śmierci |
| CN103534268B (zh) * | 2010-10-20 | 2016-05-18 | 牛津生物疗法有限公司 | 抗体 |
| US20130025987A1 (en) | 2011-07-18 | 2013-01-31 | David Batterbee | Methods and apparatus for controlling a fluid damper |
| EP2684896A1 (fr) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anticorps de la famille anti-DR5 ou bispécifique anticorps de la famille anti-DR5 multivalents et leurs procédés d'utilisation |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| NO2776305T3 (fr) | 2014-04-23 | 2018-01-27 | ||
| MX2017001946A (es) | 2014-08-12 | 2017-06-19 | Novartis Ag | Conjugados de farmacos con anticuerpos anti-cdh6. |
| UY36401A (es) | 2014-11-14 | 2016-06-30 | Novartis Ag | Conjugados anticuerpos-fármacos |
| PT3247728T (pt) * | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| CN107250161A (zh) | 2015-01-26 | 2017-10-13 | 宏观基因有限公司 | 包含dr5‑结合结构域的多价分子 |
| EP3848393A1 (fr) | 2016-05-18 | 2021-07-14 | Boehringer Ingelheim International GmbH | Molécules d'anticorps pour le traitement du cancer |
| EP3360898A1 (fr) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer |
-
2017
- 2017-02-14 EP EP17155973.5A patent/EP3360898A1/fr not_active Withdrawn
- 2017-12-21 BR BR112019011750-4A patent/BR112019011750A2/pt active Search and Examination
- 2017-12-21 PE PE2019001228A patent/PE20191251A1/es unknown
- 2017-12-21 CA CA3046591A patent/CA3046591A1/fr active Pending
- 2017-12-21 CN CN201780085628.8A patent/CN110582513B/zh active Active
- 2017-12-21 MX MX2019007511A patent/MX391650B/es unknown
- 2017-12-21 EA EA201991480A patent/EA201991480A1/ru unknown
- 2017-12-21 TW TW106144948A patent/TWI790219B/zh active
- 2017-12-21 AU AU2017384687A patent/AU2017384687B2/en not_active Expired - Fee Related
- 2017-12-21 US US15/850,895 patent/US10858438B2/en active Active
- 2017-12-21 MA MA047121A patent/MA47121A/fr unknown
- 2017-12-21 WO PCT/EP2017/084002 patent/WO2018115231A2/fr not_active Ceased
- 2017-12-21 EP EP17838041.6A patent/EP3559040B1/fr active Active
- 2017-12-21 JP JP2019534104A patent/JP7196076B2/ja active Active
- 2017-12-21 KR KR1020197018925A patent/KR102651761B1/ko active Active
-
2019
- 2019-06-17 CO CONC2019/0006320A patent/CO2019006320A2/es unknown
-
2020
- 2020-10-30 US US17/084,881 patent/US11851495B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020501586A (ja) | 2020-01-23 |
| TW201835102A (zh) | 2018-10-01 |
| JP7196076B2 (ja) | 2022-12-26 |
| BR112019011750A2 (pt) | 2019-10-29 |
| MX2019007511A (es) | 2019-09-04 |
| EP3559040A2 (fr) | 2019-10-30 |
| CO2019006320A2 (es) | 2019-06-28 |
| CN110582513A (zh) | 2019-12-17 |
| KR102651761B1 (ko) | 2024-03-26 |
| EA201991480A1 (ru) | 2020-01-15 |
| AU2017384687A1 (en) | 2019-06-13 |
| US20180179287A1 (en) | 2018-06-28 |
| WO2018115231A3 (fr) | 2018-08-02 |
| EP3559040B1 (fr) | 2026-04-08 |
| TWI790219B (zh) | 2023-01-21 |
| PE20191251A1 (es) | 2019-09-18 |
| CA3046591A1 (fr) | 2018-06-28 |
| US20210095038A1 (en) | 2021-04-01 |
| AU2017384687B2 (en) | 2025-01-23 |
| EP3360898A1 (fr) | 2018-08-15 |
| US10858438B2 (en) | 2020-12-08 |
| WO2018115231A2 (fr) | 2018-06-28 |
| US11851495B2 (en) | 2023-12-26 |
| MX391650B (es) | 2025-03-21 |
| KR20190099223A (ko) | 2019-08-26 |
| CN110582513B (zh) | 2023-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| EP3621592A4 (fr) | Polythérapies pour le traitement du cancer | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA41555A (fr) | Polythérapie pour le traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| EP3285773A4 (fr) | Polythérapie pour le traitement du cancer | |
| EP3397963A4 (fr) | Inhibition de mapk p38 pour le traitement du cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| EP3436002A4 (fr) | Combinaisons pharmaceutiques pour le traitement du cancer | |
| EP3452060A4 (fr) | Polythérapie pour le traitement du cancer | |
| MA45429A (fr) | Polythérapie pour le traitement du cancer | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3351189A4 (fr) | Instrument de traitement pour endoscope | |
| EP3400010A4 (fr) | Combinaisons anti-her2 pour le traitement des tumeurs | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| EP3362066A4 (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| EP3490561A4 (fr) | Combinaisons pour le traitement du cancer | |
| EP3400011A4 (fr) | Combinaisons anti-cd20 pour le traitement des tumeurs | |
| EP3383407A4 (fr) | Conjugués de cytarabine pour le traitement du cancer | |
| EP3630196A4 (fr) | Polythérapies pour le traitement de cancers | |
| EP3335041A4 (fr) | Biomarqueurs pour le traitement de la pelade | |
| EP3331510A4 (fr) | Thérapies combinatoires pour le traitement du cancer | |
| MA41123A (fr) | Polythérapie pour le traitement du cancer | |
| EP3503887A4 (fr) | Combinaisons pour le traitement du cancer |